1. Home
  2. TCBS vs IMMP Comparison

TCBS vs IMMP Comparison

Compare TCBS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TCBS

Texas Community Bancshares Inc.

N/A

Current Price

$16.83

Market Cap

48.6M

Sector

Finance

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.45

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCBS
IMMP
Founded
1934
1987
Country
United States
Australia
Employees
71
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.6M
58.2M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
TCBS
IMMP
Price
$16.83
$0.45
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
1.5K
21.8M
Earning Date
04-24-2026
05-12-2026
Dividend Yield
1.18%
N/A
EPS Growth
327.27
N/A
EPS
0.31
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
$16.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.10
$0.29
52 Week High
$20.00
$3.53

Technical Indicators

Market Signals
Indicator
TCBS
IMMP
Relative Strength Index (RSI) 47.27 33.72
Support Level $16.79 $0.29
Resistance Level $17.13 $1.05
Average True Range (ATR) 0.16 0.03
MACD -0.05 0.03
Stochastic Oscillator 65.63 14.24

Price Performance

Historical Comparison
TCBS
IMMP

About TCBS Texas Community Bancshares Inc.

Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: